A PHASE II STUDY OF ESTRAMUSTINE, DOCETAXEL, AND BEVACIZUMAB IN MEN WITH CASTRATE RESISTANT PROSTATE CANCER: RESULTS OF CANCER AND LEUKEMIA GROUP B (CALGB) 90006

BACKGROUND: The use of docetaxel prolongs survival for patients with castrate resistant prostate cancer (CRPC). Inhibition of vascular endothelial growth factor (VEGF) with bevacizumab may further enhance the anti-tumor effect of docetaxel and estramustine in patients with CRPC. PATIENTS AND METHODS...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Picus, Joel, Halabi, Susan, Kelly, W. Kevin, Vogelzang, Nicholas J., Whang, Young E., Kaplan, Ellen B., Stadler, Walter M., Small, Eric J.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3010428/
https://ncbi.nlm.nih.gov/pubmed/20862750
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25421
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki